Pivotal Phase III data at ASCO show Roche’s Tecentriq helps certain people with early lung cancer live significantly longer without their disease returning

NEXT STORY
OSE Immunotherapeutics and Boehringer Ingelheim Present Positive Phase 1 Results with First-in-Class SIRPα inhibitor BI 765063 in Advanced Solid Tumors at ASCO 2021
PREV STORY
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Arcimoto, Churchill, Emergent BioSolutions, and Verus International and Encourages Investors to Contact the Firm
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Centrexion Therapeutics to Announce CNTX-4975 Trial Results at the European League Against Rheumatism’s (EULAR) 2019 Annual European Congress of Rheumatology

author_avatar
NASDAQ Market News

Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents

author_avatar
NASDAQ Market News

Brandywine Realty Trust Announces First Quarter Results and Adjusts 2020 Guidance

author_avatar
NASDAQ Market News